A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Status:
Recruiting
Trial end date:
2024-05-07
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D[s]) in B cell
non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate
the safety of JNJ-64264681 at the RP2D(s) in Part 2.